Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort.

Sperl, Jan

Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort. [electronic resource] - Kidney & blood pressure research 2018 - 594-605 p. digital

Publication Type: Journal Article

1423-0143

10.1159/000488965 doi


2-Naphthylamine
Anilides--therapeutic use
Antihypertensive Agents--therapeutic use
Antiviral Agents--adverse effects
Carbamates--therapeutic use
Cyclopropanes
Drug Therapy, Combination
Female
Genotype
Hepacivirus--drug effects
Hepatitis C, Chronic--complications
Humans
Kidney Failure, Chronic--therapy
Lactams, Macrocyclic
Macrocyclic Compounds--therapeutic use
Male
Middle Aged
Proline--analogs & derivatives
Renal Insufficiency--therapy
Ritonavir--therapeutic use
Sulfonamides--therapeutic use
Treatment Outcome
Uracil--analogs & derivatives
Valine